Frontiers in Oncology (Feb 2024)

Not only a therapeutic target; mTOR in Hodgkin lymphoma and acute lymphoblastic leukemia

  • Miguel Enrique Cuéllar Mendoza,
  • Miguel Enrique Cuéllar Mendoza,
  • Francisco Raúl Chávez Sánchez,
  • Elisa María Dorantes Acosta,
  • Ana María Niembro Zúñiga,
  • Rosana Pelayo,
  • Marta Zapata Tarrés

DOI
https://doi.org/10.3389/fonc.2024.1304605
Journal volume & issue
Vol. 14

Abstract

Read online

IntroductionThe mechanistic/mammalian target of rapamycin (mTOR) is a serine/threonine kinase, which is downregulated or upregulated and is implicated in different types of cancer including hematologic neoplasms, skin prostate, and head and neck cancer.AimThe aim of this study was to explore the current knowledge of mTOR signaling in acute lymphoblastic leukemia and Hodgkin lymphoma.MethodsA systematic review was performed according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, searching PubMed, Discovery Service for National Autonomous University of Mexico, Registro Nacional de Instituciones y Empresas Científicas y Tecnológicas (RENIECYT), and Scientific Electronic Library Online (SciELO) from 1994 to 2023. A total of 269 papers were identified for acute lymphoblastic leukemia, but based on specific criteria, 15 were included; for Hodgkin lymphoma, 110 papers were identified, but 5 were included after manual searching.ResultsA total of 20 papers were evaluated, where mTOR activity is increased in patients with Hodgkin lymphoma and acute lymphoblastic leukemia by different molecular mechanisms.ConclusionsmTOR activity is increased in patients with both hematologic neoplasms and NOTCH; interleukin 4, 7, and 9, and nuclear proteins have been studied for their role in the activation of mTOR signaling.

Keywords